US appeals court revives Glaxo US$235.5 million verdict against Teva

FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference hold by its CEO, Kare Schultz, to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019. REUTERS/Amir CohenShare this contentREUTERS: A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc US$235.5 million for selling a generic version of Glaxo's heart drug Coreg.

Glaxo had won US approval to market Coreg, whose chemical name is carvedilol, to treat hypertension, left ventricular dysfunction after a heart attack and congestive heart failure. Glaxo, whose patent expired in 2015, sued Teva, and a Delaware jury ordered the Israeli drugmaker to pay US$234.1 million for lost profit plus US$1.4 million in royalties.U.S. District Judge Leonard Stark overturned the verdict, saying other factors could have caused doctors to prescribe generic Coreg, including for congestive heart failure.

Chief Judge Sharon Prost dissented, citing Congress' desire for efficient procedures to help low-cost generic drugs enter the marketplace.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Earnings from whistleblower Edward Snowden's book should go to US government, court rulesWASHINGTON (REUTERS) - The United States is entitled to more than US$5.2 million (S$7 million) from former National Security Agency (NSA) contractor Edward Snowden's book royalties, a federal court ruled this week, according to the US Department of Justice.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »